Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart drug may tame baby blood vessel growth

NCT ID NCT00744185

Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested if the beta-blocker propranolol could control the growth of infantile hemangiomas (non-dangerous blood vessel growths) in babies under 4 months old. The trial was terminated early and only enrolled 14 infants. The goal was to measure changes in hemangioma thickness after one month of treatment compared to a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

14 people

The number who actually took part.

Start date

Oct 2008

Finished

Apr 2010

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 4 months

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Infant aged less than 4 months * Infant with one or more hemangiomas sized more than 1 cm diameter * Infant not threatening for vital or functional structure and for which no treatment would be proposed * Informed consent * Patient with social insurance. Exclusion Criteria: * Alarming hemangioma (s) (complicated forms or localization at risk) * Cardiac pathology (cardiac malformation, heart failure, cardiac arrhythmias, pulmonary hypertension) * Asthma * Bronchopulmonary dysplasia * Bronchiolitis * Raynaud syndrome * Phéochromocytoma * Development of serious form of hemangioma (bleeding, necrosis, ulceration, infection, respiratory distress) requiring standard treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemangioma, capillary are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

capillary hemangioma capillary infantile hemangioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemangioma, capillary

Contacts and locations

Locations

  • Dermatologie Pédiatrique

    Bordeaux, 33 076, France